Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Tax Provisions: 2020-2025

Historic Tax Provisions for Pharming Group N.V (PHAR) over the last 4 years, with Jun 2025 value amounting to -$5.6 million.

  • Pharming Group N.V's Tax Provisions fell 286.51% to -$5.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.3 million, marking a year-over-year decrease of 167.96%. This contributed to the annual value of $3.3 million for FY2024, which is 328.76% up from last year.
  • Per Pharming Group N.V's latest filing, its Tax Provisions stood at -$5.6 million for Q2 2025, which was down 295.52% from $2.9 million recorded in Q4 2024.
  • Pharming Group N.V's Tax Provisions' 5-year high stood at $7.1 million during Q4 2021, with a 5-year trough of -$5.7 million in Q2 2021.
  • Over the past 3 years, Pharming Group N.V's median Tax Provisions value was $2.4 million (recorded in 2023), while the average stood at $550,667.
  • Per our database at Business Quant, Pharming Group N.V's Tax Provisions skyrocketed by 970.14% in 2021 and then slumped by 17,983.86% in 2022.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Tax Provisions stood at $7.1 million in 2021, then dropped by 14.27% to $6.1 million in 2022, then slumped by 166.14% to -$4.0 million in 2023, then skyrocketed by 171.62% to $2.9 million in 2024, then crashed by 286.51% to -$5.6 million in 2025.
  • Its Tax Provisions stands at -$5.6 million for Q2 2025, versus $2.9 million for Q4 2024 and -$2.5 million for Q3 2024.